First Affirmative Financial Network Sells 1,363 Shares of Danaher Co. (NYSE:DHR)

First Affirmative Financial Network cut its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 25.0% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,088 shares of the conglomerate's stock after selling 1,363 shares during the period. First Affirmative Financial Network's holdings in Danaher were worth $838,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of DHR. Vanguard Group Inc. raised its position in shares of Danaher by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock worth $13,715,641,000 after acquiring an additional 315,912 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Danaher by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after acquiring an additional 315,446 shares in the last quarter. Norges Bank bought a new position in shares of Danaher in the 4th quarter worth $2,130,740,000. Bank of New York Mellon Corp raised its position in shares of Danaher by 5.4% in the 4th quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate's stock worth $1,971,609,000 after acquiring an additional 441,012 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Danaher by 14.3% in the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after acquiring an additional 992,594 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Up 2.1%

Danaher stock opened at $196.13 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The business's 50-day simple moving average is $191.34 and its two-hundred day simple moving average is $212.34. The company has a market cap of $140.36 billion, a PE ratio of 37.15, a PEG ratio of 2.66 and a beta of 0.80. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. Equities analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.65%. Danaher's dividend payout ratio (DPR) is 24.85%.

Insider Buying and Selling

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

DHR has been the subject of several recent research reports. HSBC reduced their price target on Danaher from $270.00 to $240.00 in a research report on Friday, April 25th. UBS Group reduced their target price on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Robert W. Baird reduced their target price on Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. The Goldman Sachs Group reduced their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Finally, Barclays upped their target price on Danaher from $205.00 to $215.00 and gave the company an "overweight" rating in a research report on Tuesday, April 22nd. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average target price of $263.24.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.